Nautilus projects 15%-20% expense growth in 2026 as early access program ramps up
Source: SeekingAlpha
2026-02-26 13:38:56 ET
More on Nautilus Biotechnology
- Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
- Nautilus Biotechnology GAAP EPS of -$0.11 beats by $0.03
- Seeking Alpha’s Quant Rating on Nautilus Biotechnology
- Historical earnings data for Nautilus Biotechnology
- Financial information for Nautilus Biotechnology
Read the full article on Seeking Alpha
For further details see:
Nautilus projects 15%-20% expense growth in 2026 as early access program ramps up
Nautilus Biotechnology Inc.
NASDAQ: NAUT
NAUT Trading
-1.0% G/L:
$2.47 Last:
46,874 Volume:
$2.48 Open:
NAUT Latest News
March 02, 2026 08:00:00 am
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
February 26, 2026 08:00:00 am
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
February 24, 2026 08:00:00 am
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
NAUT Stock Data
$266,503,807
49,511,608
N/A
20
N/A
Biotechnology & Life Sciences
Healthcare
US
Seattle
